| McMillan Shakespeare Limited (MMS) ORDINARY FULLY PAID |
Industrials |
$1,127 |
Appendix 4D and Half Year Report
|
27 Feb 2025 8:07AM |
$14.060 |
$16.180 |
risen by
15.08%
|
|
MMS - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from continuing operations rose by 7.9% to $276,829,000.
- Net profit after tax attributable to members was $45,224,000.
- Interim dividend declared at 71 cents per share.
- No significant changes in the nature of activities during the period.
- The Simply Stronger program aims to enhance digital experiences and operational efficiencies.
- Normalised UNPATA from continuing operations was $49,634,000.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Medibank Private Limited (MPL) ORDINARY FULLY PAID |
Financials |
$13,495 |
Dividend/Distribution - MPL
|
27 Feb 2025 8:07AM |
$4.020 |
$4.900 |
risen by
21.89%
|
|
| GTN Limited (GTN) ORDINARY FULLY PAID |
Communication Services |
$117 |
Update - Notification of buy-back - GTN
|
27 Feb 2025 8:07AM |
$0.535 |
$0.610 |
risen by
14.02%
|
|
| MAAS Group Holdings Limited (MGH) ORDINARY FULLY PAID |
Industrials |
$1,542 |
Update - Notification of buy-back - MGH
|
27 Feb 2025 8:07AM |
$3.850 |
$4.250 |
risen by
10.39%
|
|
| Vitura Health Limited (VIT) ORDINARY FULLY PAID |
Health Care |
$43 |
Change of Director's Interest Notice
|
27 Feb 2025 8:07AM |
$0.087 |
$0.065 |
fallen by
25.29%
|
|
| Medibank Private Limited (MPL) ORDINARY FULLY PAID |
Financials |
$13,495 |
HY25 Results - Appendix 4D and Financial Report
|
27 Feb 2025 8:07AM |
$4.020 |
$4.900 |
risen by
21.89%
|
|
MPL - Price-sensitive ASX Announcement
Full Release
Key Points
- Group operating profit increased by 12.7% to $360.1 million.
- Health insurance revenue rose by 5.0% to $4,113.9 million.
- Net profit after tax attributable to shareholders decreased by 0.8% to $340.3 million.
- Interim dividend declared at 7.8 cents per share.
- Strong performance in the Medibank Health segment with a 40.8% profit increase.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Imricor Medical Systems Inc (IMR) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$487 |
FY24 Results Investor Presentation
|
27 Feb 2025 8:07AM |
$1.460 |
$1.520 |
risen by
4.11%
|
|
IMR - Price-sensitive ASX Announcement
Full Release
Key Points
- Imricor's technology enables cardiac procedures without ionizing radiation.
- Revenue of US $959k in FY2024, up 56% from the previous year.
- The company is the only one globally with MRI-compatible devices for cardiac procedures.
- Imricor's products are approved in 31 countries, with growth expected in several markets.
- The NorthStar 3D Mapping System is critical for the future of iCMR labs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| L1 Long Short Fund Limited (LSF) ORDINARY FULLY PAID |
Financials |
$1,811 |
Net Tangible Asset Backing
|
27 Feb 2025 8:07AM |
$2.740 |
$2.880 |
risen by
5.11%
|
|
| IDP Education Limited (IEL) ORDINARY FULLY PAID |
Consumer Discretionary |
$994 |
Dividend/Distribution - IEL
|
27 Feb 2025 8:07AM |
$11.790 |
$3.570 |
fallen by
69.72%
|
|
| Medibank Private Limited (MPL) ORDINARY FULLY PAID |
Financials |
$13,495 |
Medibank to return $160m to customers
|
27 Feb 2025 8:07AM |
$4.020 |
$4.900 |
risen by
21.89%
|
|
| IDP Education Limited (IEL) ORDINARY FULLY PAID |
Consumer Discretionary |
$994 |
H1 FY25 Investor Presentation
|
27 Feb 2025 8:07AM |
$11.790 |
$3.570 |
fallen by
69.72%
|
|
IEL - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue of A$475.4 million down 16%
- Adjusted EBIT of A$92.7 million down 40%
- Student Placement volumes down 15%
- English Language Testing volumes down 19%
- Overhead costs reduced by 14%
- GOCF conversion rate improved to 64%
- Average price growth of 14% in Student Placement
- Maintained student NPS above 70, reflecting positive student experience
- Strong focus on technology and innovation for efficiency and user experience
- Positioned to expand market share despite challenging conditions
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Imricor Medical Systems Inc (IMR) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$487 |
Imricor Releases FY24 Results
|
27 Feb 2025 8:07AM |
$1.460 |
$1.520 |
risen by
4.11%
|
|
IMR - Price-sensitive ASX Announcement
Full Release
Key Points
- First module submitted and returned by US FDA with no deficiencies
- NorthStar submitted for CE Mark approval in Europe
- First MRI guided ablation on US soil performed at Johns Hopkins as part of VISABL-AFL
- Saudi FDA approval received, registration completed in Qatar opening Middle East
- CE Mark approval of MR Vision diagnostic catheter
- VISABL-AFL global pivotal trial commences enrolment in France, US and Switzerland
- Global rollout underway with new site activations in France, Netherlands, Croatia and Switzerland
- Installation complete in Hungary, first procedures being scheduled
- First purchase orders received from Qatar initiating expansion into Middle East
- Group revenue of US$959k + 56% on prior year
- Operating costs well contained down 1% to $17.3m including R&D investment
- Strong balance sheet US$15.7m cash in place to fund major milestones in 2025
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| IDP Education Limited (IEL) ORDINARY FULLY PAID |
Consumer Discretionary |
$994 |
H1 FY25 Results Announcement
|
27 Feb 2025 8:07AM |
$11.790 |
$3.570 |
fallen by
69.72%
|
|
IEL - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue of $475.4 million, down 16%
- Adjusted EBIT of $92.7 million, down 40%
- Overhead costs down 14% to $167.8 million
- Student Placement volumes decreased by 27%
- English Language Testing volumes down 24%
- Interim dividend of 9.0 cents per share declared
- Cost discipline and market share growth emphasized
- Long-term growth drivers for international education remain positive
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Change Financial Limited (CCA) ORDINARY FULLY PAID |
Financials |
$45 |
H1 FY25 Investor Presentation
|
27 Feb 2025 8:07AM |
$0.067 |
$0.065 |
fallen by
2.99%
|
|
| Change Financial Limited (CCA) ORDINARY FULLY PAID |
Financials |
$45 |
H1 FY25 Results Summary
|
27 Feb 2025 8:07AM |
$0.067 |
$0.065 |
fallen by
2.99%
|
|
| IDP Education Limited (IEL) ORDINARY FULLY PAID |
Consumer Discretionary |
$994 |
H1 FY 25 Interim Financial Report
|
27 Feb 2025 8:07AM |
$11.790 |
$3.570 |
fallen by
69.72%
|
|
IEL - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue for H1 FY25 decreased by 18% to $475.4 million.
- Net profit after tax fell by 39% to $59.7 million.
- Student placement revenue dropped by 15% to $244.2 million.
- English language testing revenue declined by 22%.
- Revenue decline was attributed to decreased student volumes in major markets.
- Australasia segment recorded a 27% revenue increase.
- Net debt increased to $191 million.
- Cash and cash equivalents at the end of the half-year were $156.9 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Solvar Limited (SVR) ORDINARY FULLY PAID |
Financials |
$323 |
Update - Notification of buy-back - SVR
|
27 Feb 2025 8:06AM |
$1.440 |
$1.640 |
risen by
13.89%
|
|
| Change Financial Limited (CCA) ORDINARY FULLY PAID |
Financials |
$45 |
Half Yearly Report and Accounts
|
27 Feb 2025 8:06AM |
$0.067 |
$0.065 |
fallen by
2.99%
|
|
CCA - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 61% to US$7,193,111 for the half year ended 31 December 2024.
- Operating loss for the period was US$1,731,201, an increase of 13% from last year.
- The company aims for over 30% revenue growth and a positive EBITDA in FY25.
- Exit from the US market expected to significantly reduce operating expenses.
- Focus on solidifying client base and building new partnerships.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Imricor Medical Systems Inc (IMR) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$487 |
Appendix 4E and FY24 Financial Accounts
|
27 Feb 2025 8:06AM |
$1.460 |
$1.520 |
risen by
4.11%
|
|
IMR - Price-sensitive ASX Announcement
Full Release
Key Points
- Imricor Medical Systems Inc focuses on MRI-guided technology for cardiac procedures.
- Total revenues increased to $959,424 in 2024 from $615,568 in 2023.
- The company reported a net loss of approximately $29.69 million for 2024.
- There are concerns regarding the company's ability to continue as a going concern.
- The company has faced recurring operational losses and negative cash flows.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Brambles Limited (BXB) ORDINARY FULLY PAID |
Industrials |
$31,473 |
Update - Notification of buy-back - BXB
|
27 Feb 2025 8:06AM |
$20.980 |
$23.020 |
risen by
9.72%
|
|
| SDI Limited (SDI) ORDINARY FULLY PAID |
Health Care |
$99 |
HY24 Investor Results Presentation
|
27 Feb 2025 8:06AM |
$0.845 |
$0.835 |
fallen by
1.18%
|
|
SDI - Price-sensitive ASX Announcement
Full Release
Key Points
- HY25 revenue decreased to $51.5 million.
- Gross profit margin increased to 63.5%.
- Strong growth in European and Brazilian markets.
- Continued investment in operational efficiencies.
- Montrose manufacturing upgrade project underway.
- Launch of new products planned in the next 12 months.
- Commitment to ESG initiatives and reporting.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| BETR Entertainment Limited (BBT) ORDINARY FULLY PAID |
Consumer Discretionary |
$277 |
H1 FY25 Results & Investor Presentation
|
27 Feb 2025 8:06AM |
$0.370 |
$0.270 |
fallen by
27.03%
|
|
BBT - Price-sensitive ASX Announcement
Full Release
Key Points
- Turnover of $645.1 million, a 116% increase year-on-year.
- Gross Win Margin increased to 14.2%.
- Net Win Margin improved to 10.4%.
- Normalized EBITDA positive ahead of schedule.
- Successful migration from betr platform in 59 days.
- Focus on customer retention and targeted marketing.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| SDI Limited (SDI) ORDINARY FULLY PAID |
Health Care |
$99 |
Media Release Dec 24 Results
|
27 Feb 2025 8:06AM |
$0.845 |
$0.835 |
fallen by
1.18%
|
|
SDI - Price-sensitive ASX Announcement
Full Release
Key Points
- Net profit after tax increased by 3.5% to $3.8 million.
- Sales decreased by 1.3% to $51.5 million.
- Gross product margin improved to 63.5%, an increase of 200 bps.
- Operating expenses rose by 4.3% compared to the previous year.
- Interim ordinary dividend maintained at 1.5 cents per share.
- Sales growth noted in Aesthetic products, particularly Stela.
- Challenges faced in Middle Eastern and Asian markets.
- Focus on achieving manufacturing and logistical efficiencies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Paragon Care Limited (PGC) ORDINARY FULLY PAID |
Health Care |
$670 |
HY25 Investor Presentation
|
27 Feb 2025 8:06AM |
$0.530 |
$0.405 |
fallen by
23.58%
|
|
PGC - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 28% to $1.85 billion for HY25.
- Net profit after tax rose to $13.2 million, an increase of 85.9%.
- Successful merger with CH2 Holdings Pty Ltd completed on 3 June 2024.
- Targeting annual synergies of $5 million for FY25 and $12 million for FY26.
- Operational efficiencies and cost rationalization are key strategic focuses.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| SDI Limited (SDI) ORDINARY FULLY PAID |
Health Care |
$99 |
Dividend/Distribution - SDI
|
27 Feb 2025 8:06AM |
$0.845 |
$0.835 |
fallen by
1.18%
|
|
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
